
Sign up to save your podcasts
Or


Send us a text
New therapeutic options are now available for HR+ MBC. Dr. Virginia Kaklamani will discuss endocrine therapy resistance, liquid biopsy/blood test, mutations, and treatment sequencing of targeted therapy. You will learn about oral selective estrogen receptor degraders (SERDS), clinical trials, and more.
By SHARE Cancer Support5
5858 ratings
Send us a text
New therapeutic options are now available for HR+ MBC. Dr. Virginia Kaklamani will discuss endocrine therapy resistance, liquid biopsy/blood test, mutations, and treatment sequencing of targeted therapy. You will learn about oral selective estrogen receptor degraders (SERDS), clinical trials, and more.

38,777 Listeners

9,750 Listeners

67 Listeners

113,075 Listeners

56,825 Listeners

12,761 Listeners

10,518 Listeners

3,187 Listeners